Kidney Cancer Canada - Survey on Patient experience with Belzutifan (Welireg) 2024 |
Introduction
Kidney Cancer Canada is developing a submission for the Canada's Drug Agency for the new treatment belzutifan for patients with advanced renal cell carcinoma (RCC).
This is good news as patients require new therapies that improve outcomes and address currently unmet treatment needs.
This is good news as patients require new therapies that improve outcomes and address currently unmet treatment needs.
We are seeking insights from patients (or their caregivers) who have experience with this treatment (belzutifan/Welireg). Your participation in this survey will help inform our submission for the drug under review.
This survey will take 10 - 15 minutes to complete. We ask that you complete the survey by November 26, 2024.
If you have any questions about this survey, please write to us at info@kidneycancercanada.ca and include "Patient and Caregiver Survey" in the subject line of the email.
Privacy Policy: All survey data is being collected by Kidney Cancer Canada for the purposes of research, including a submission to Canada's Drug Agency. To ensure patient privacy and confidentiality, individual responses will not be identifiable. Although selected quotations may be used, no reference to patient name or any other identifying information will be included.
Thank you for your participation!
For more information about Kidney Cancer Canada, please visit: kidneycancercanada.ca
This survey will take 10 - 15 minutes to complete. We ask that you complete the survey by November 26, 2024.
If you have any questions about this survey, please write to us at info@kidneycancercanada.ca and include "Patient and Caregiver Survey" in the subject line of the email.
Privacy Policy: All survey data is being collected by Kidney Cancer Canada for the purposes of research, including a submission to Canada's Drug Agency. To ensure patient privacy and confidentiality, individual responses will not be identifiable. Although selected quotations may be used, no reference to patient name or any other identifying information will be included.
Thank you for your participation!
For more information about Kidney Cancer Canada, please visit: kidneycancercanada.ca